Fulvadon contains fulvestrant, a hormonal therapy specifically designed to treat hormone receptor-positive breast cancer in postmenopausal women. It is often used when the cancer has returned or progressed despite other hormone therapies like tamoxifen or aromatase inhibitors. Fulvadon works by targeting the cancer’s dependence on estrogen for growth and helps slow or stop disease progression.

Given by intramuscular injection, usually once every two to four weeks, Fulvadon provides a convenient, maintenance-based approach in advanced breast cancer care.

Mechanism of Action

Fulvestrant, the active component of Fulvadon, is a selective estrogen receptor degrader, also known as a SERD. It binds to estrogen receptors on cancer cells and disrupts their function, preventing estrogen from stimulating the tumor. More importantly, it promotes the breakdown of these receptors, reducing the number available to be activated.

This dual mechanism—blocking and degrading the receptors—helps reduce cancer cell growth more effectively than therapies that merely block estrogen’s activity without removing the receptors.

Uses

Fulvadon is primarily used for:

• Hormone receptor-positive metastatic breast cancer in postmenopausal women

• Cases where the cancer has progressed after prior anti-estrogen treatments

• Sometimes used in combination with other targeted agents to enhance treatment outcomes

  Adverse Effects

  Most side effects from Fulvadon are manageable and mild, but it is important for patients to be aware of them and communicate any concerns with their doctor.

  Common Side Effects

  • Injection site pain or swelling

  • Hot flashes

  • Weakness or fatigue

  • Nausea

  • Headache

  • Joint or muscle discomfort